Letter to the editor: Community-based phase II trial of PCR for CLL/SLL patients [1]

Cancer Biotherapy and Radiopharmaceuticals

Volumn 22, Issue 5, 2007, Pages 713-714

  Kay, Neil E ^a   Shanafelt, Tait D ^a   Byrd, John C ^b   Grever, Michael R ^b  

^a MAYO CLINIC   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; PENTOSTATIN; RITUXIMAB; ANTINEOPLASTIC AGENT; CD20 ANTIGEN; MONOCLONAL ANTIBODY;

ADULT; AGED; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DATA ANALYSIS; DRUG DOSE TITRATION; DRUG SAFETY; HIGH RISK PATIENT; HUMAN; LETTER; NEPHROTOXICITY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RETREATMENT; UNSPECIFIED SIDE EFFECT; B CELL LEUKEMIA; DRUG COMBINATION; IMMUNOLOGY; NOTE; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE II AS TOPIC; CYCLOPHOSPHAMIDE; DRUG THERAPY, COMBINATION; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; PENTOSTATIN; TREATMENT OUTCOME;

EID: 35848946154     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2007.0424     Document Type: Letter

References (6)

1. Dillman RO, Schreeder MT, Hon JK, et al. Communitybased phase II trial of pentostatin, cyclophosphamide, and rituximab (PCR) biochemotherapy in chronic lymphocytic leukemia and small lymphocytic lymphoma. Cancer Biother Radiopharm 2007;22:185.
2. Kay NE, Geyer SM, Call TG, et al. Combination chemoimmunotherapy with pentostatin, cyclophosphamide and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B-chronic lymphocytic leukemia. Blood 2007;109:405.
3. Shanafelt TD, Lin T, Geyer SM, et al. Pentostatin, cyclophosphamide, and rituximab regimen in older patients with chronic lymphocytic leukemia. Cancer 2007;109:2291.
4. Grever M, Kopecky K, Foucar MK, et al. Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: An intergroup study. J Clin Oncol 1995;13:974.
5. Lamanna N, Kalaycio M, Maslak P, et al. Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia. J Clin Oncol 2006;24:1575.
6. Eichhorst BF, Busch R, Hopfinger G, et al. Fludarabine plus cyclophosphamide versus fludarabine alone in firstline therapy of younger patients with chronic lymphocytic leukemia. Blood 2006;107:885.